Selumetinib in Combination With Gefitinib in NSCLC Patients
Status:
Completed
Trial end date:
2018-03-08
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized, multicenter phase Ib/II study, which is composed of a
phase Ib dose escalation part and a phase II dose expansion part. Patients will receive
selumetinib in combination with gefitinib 250mg daily. This study will enroll EGFR-mutated
NSCLC patients who have developed acquired resistance to EGFR TKI treatment.